Study details
Enrolling now
Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder
Rutgers, The State University of New Jersey
NCT IDNCT06642181ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
224
Study length
about 1.2 years
Ages
18–55
Locations
1 site in NJ
About this study
This trial is testing whether combining guanfacine with mindfulness meditation helps people who are already taking buprenorphine for opioid use disorder stay sober longer. This treatment involves taking a medication called guanfacine and participating in a mindfulness program.
Based on ClinicalTrials.gov records.
What participants do
- 1.Participate in Mindfulness Oriented Recovery Enhancement (MORE)
- 2.Take Guanfacine pharmacotherapy
PhasePhase 1
DrugGuanfacine pharmacotherapy
Routeoral
Primary goalAnxiety
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
CARDIOVASCULAR SYSTEM
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Anxiety, Heart Rate, Mood
Body systems
Psychiatry / Mental Health